Utidelone
- Generic Name
- Utidelone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
Utidelone (UTD1), a novel microtubule stabilizing agent, is an epothilone B analogue produced by genetic engineering. It is under investigation in clinical trials for various cancers.
- Indication
联合卡培他滨，用于既往接受过至少一种化疗方案的复发或转移性乳腺癌患者。
- Associated Conditions
- -
- Associated Therapies
- -
Eyes on Asia: VC hits China, BioStar IPO, and Legend splits from GenScript
LaNova Medicines raised $42m in Series C1 funding and outlicensed candidates to AstraZeneca and Turning Point Therapeutics. XellSmart Biomedical secured $28m for stem cell therapies targeting neurodegenerative diseases. BioStar Pharma raised $42m in a Hong Kong IPO for its lead drug Utidelone. Legend Biotech decoupled from GenScript Biotech, citing good corporate governance.
Clariant to launch eight new high-performing excipients at the CPHI Milan 2024
Clariant introduces new health care products at CPHI Milan 2024, including VitiPure LEX 3350 S, VitiPure LEX 4000 S, and Polyglykol 1450 S, addressing API delivery and bioavailability challenges. VitiPure Superior line offers nearly colorless, highly-purified excipients for sensitive APIs and low microbial loads, while VitiPure HCO is developed for tablet formulations and topical applications.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath